Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma

Authors:
Open Access
Publisher website
Google Scholar
Abstract
No abstract available
Funding Information
  • Eli Lilly and Company
  • Takeda Pharmaceuticals U.S.A.
  • Pfizer (B9991002, B9991003)
  • Merck KGaA
  • AstraZeneca
  • Exelixis
  • Genentech
  • Alexion Pharmaceuticals
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Novartis
  • National Institutes of Health
  • Roche
  • U.S. Department of War
  • American Society of Clinical Oncology
  • National Cancer Institute
  • National Comprehensive Cancer Network
  • GlaxoSmithKline
  • Bayer Fund
  • Merck
  • Shionogi

This publication has 18 references indexed in Scilit: